TR-107 and Capivasertib Synergistically Inhibit Pancreatic Cancer Organoid Growth In Vitro

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States, highlighting the need for effective therapeutic strategies. Oxidative phosphorylation (OXPHOS) has emerged as a promising therapeutic target due to metabolic reprogramming and the pro-survival role of mitochondria in PDAC. The mitochondrial ClpXP complex, composed of the AAA+ ATPase ClpX and the peptidase ClpP, regulates mitochondrial homeostasis through protein degradation. Madera Therapeutics has developed novel ClpP activators, including TR-107. Here, we demonstrate that TR-107 reduces viability in four PDAC organoids and four cell lines at low-nanomolar concentrations while decreasing ClpX expression in a dose-dependent manner. Transcriptomic analysis revealed alterations in ferroptosis, amino acid metabolism, and HIF-1α signaling pathways. Notably, TR-107 retained its efficacy and mechanism of action under hypoxic conditions. Furthermore, TR-107 synergized with the AKT inhibitor capivasertib to suppress cell viability and modulate downstream signaling pathways. Collectively, these findings identify TR-107 as a promising therapeutic candidate that targets the mitochondrial ClpXP complex, disrupts mitochondrial function, and induces cellular stress and metabolic dysregulation. These effects may provide opportunities for combination therapies to improve treatment outcomes in PDAC.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.13.766013
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

TR-107 and Capivasertib Synergistically Inhibit Pancreatic Cancer Organoid Growth In Vitro

Agnieszka B. Bialkowska, Aisharja Mojumdar, Edwin J. Iwanowicz, Lee M. Graves et al.
4 links
bioRxiv (Cold Spring Harbor Laboratory)
Pancreatic and Hepatic Oncology Research
preprint

TR-107 and Capivasertib Synergistically Inhibit Pancreatic Cancer Organoid Growth In Vitro

Agnieszka B. Bialkowska, Aisharja Mojumdar, Edwin J. Iwanowicz, Lee M. Graves, Catalina Vera, Mia Kotikovski, Joseph F. LaComb, Sahaana Kesavan
preprint en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States, highlighting the need for effective therapeutic strategies. Oxidative phosphorylation (OXPHOS) has emerged as a promising therapeutic target due to metabolic reprogramming and the pro-survival role of mitochondria in PDAC. The mitochondrial ClpXP complex, composed of the AAA+ ATPase ClpX and the peptidase ClpP, regulates mitochondrial homeostasis through protein degradation. Madera Therapeutics has developed novel ClpP activators, including TR-107. Here, we demonstrate that TR-107 reduces viability in four PDAC organoids and four cell lines at low-nanomolar concentrations while decreasing ClpX expression in a dose-dependent manner. Transcriptomic analysis revealed alterations in ferroptosis, amino acid metabolism, and HIF-1α signaling pathways. Notably, TR-107 retained its efficacy and mechanism of action under hypoxic conditions. Furthermore, TR-107 synergized with the AKT inhibitor capivasertib to suppress cell viability and modulate downstream signaling pathways. Collectively, these findings identify TR-107 as a promising therapeutic candidate that targets the mitochondrial ClpXP complex, disrupts mitochondrial function, and induces cellular stress and metabolic dysregulation. These effects may provide opportunities for combination therapies to improve treatment outcomes in PDAC.

bioRxiv (Cold Spring Harbor Laboratory)
University of North Carolina at Chapel Hill (US), Stony Brook University (US)
Stony Brook University, National Institutes of Health
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon